Fig. 1From: Tyrosine-kinase inhibitor combined with iodine-125 seed brachytherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: a propensity-matched studyFlowchart of patient selection. HCC hepatocellular carcinoma, TACE transarterial chemoembolization, TKI-I tyrosine-kinase inhibitor combined with iodine-125 seed brachytherapy, TKI tyrosine-kinase inhibitor, HAIC hepatic arterial infusion chemotherapy, PT prothrombin timeBack to article page